Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PACB

PACB - Pacific Biosciences of California Stock Price, Fair Value and News

$2.38-0.19 (-7.39%)
Market Closed

4/100

PACB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

4/100

PACB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.06

Target 3M

$2.32

Target 6M

$2.19

PACB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PACB Price Action

Last 7 days

-1.6%

Last 30 days

39.2%

Last 90 days

22.7%

Trailing 12 Months

47.8%

PACB RSI Chart

PACB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PACB Valuation

Market Cap

718.5M

Price/Earnings (Trailing)

-1.43

Price/Sales (Trailing)

4.65

EV/EBITDA

-1.35

Price/Free Cashflow

-5.69

PACB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.06

Target 3M

$2.32

Target 6M

$2.19

PACB Fundamentals

PACB Revenue

Revenue (TTM)

154.6M

Rev. Growth (Yr)

-3.82%

Rev. Growth (Qtr)

-3.33%

PACB Earnings

Earnings (TTM)

-503.6M

Earnings Growth (Yr)

37.42%

Earnings Growth (Qtr)

9.37%

PACB Profitability

Operating Margin

25.41%

EBT Margin

-325.52%

Return on Equity

-1.4K%

Return on Assets

-62.71%

Free Cashflow Yield

-17.57%

PACB Investor Care

Shares Dilution (1Y)

10.24%

Diluted EPS (TTM)

-2.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025152.4M156.1M154.6M0
2024200.4M188.9M173.1M154.0M
2023134.0M146.1M169.5M200.5M
2022134.7M139.5M137.0M128.3M
202192.3M105.8M121.6M130.5M
202090.1M82.5M79.7M78.9M
201975.7M78.7M82.5M90.9M
201887.9M89.4M84.0M78.6M
201796.5M95.8M94.3M93.5M
201694.3M90.1M101.3M90.7M
201566.6M80.1M73.4M92.8M
201434.2M39.6M52.8M60.6M
201321.5M20.3M24.9M28.2M
201243.6M40.3M32.5M26.0M
20119.7M17.8M25.8M33.9M
20100001.7M
Get all data in R, Python etc through our Historical Stock Data APIs

About Pacific Biosciences of California

PACB
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
 CEO
 WEBSITEpacb.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES769

Pacific Biosciences of California Frequently Asked Questions

PACB is the stock ticker symbol of Pacific Biosciences of California. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Pacific Biosciences of California is 718.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PACB's fair value in chart for subscribers.

The fair value guage provides a quick view whether PACB is over valued or under valued. Whether Pacific Biosciences of California is cheap or expensive depends on the assumptions which impact Pacific Biosciences of California's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PACB.

As of Wed Jan 28 2026, PACB's PE ratio (Price to Earnings) is -1.43 and Price to Sales (PS) ratio is 4.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PACB PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Pacific Biosciences of California has provided -0.14 (multiply by 100 for percentage) rate of return.